Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS Patients

Drug Category : Array
Conference Category : Array
Lead Author : Lovett-Racke A, Fox E et al.
Published Date : 26/05/2017
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Final%202017%20CMSC%20Lovett-Racke%20TGTX.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top